share_log

Intelligent Bio Solutions | 10-Q: Q1 2025 Earnings Report

Intelligent Bio Solutions | 10-Q: Q1 2025 Earnings Report

Intelligent Bio Solutions | 10-Q：2025财年一季报
美股SEC公告 ·  2024/11/07 05:43

Moomoo AI 已提取核心信息

Intelligent Bio Solutions Inc. reported Q1 FY2025 revenue of $872,287, a 10% increase from $796,094 in Q1 FY2024, driven by customer base expansion across 19 countries. Gross profit margin improved to 39.8% from 29.2% year-over-year, reflecting enhanced production efficiency and reduced direct costs. The company secured 22 new accounts during the quarter.Development and regulatory expenses rose significantly to $948,752 from $103,947 last year as the company advanced its FDA 510(k) clinical study plan, including a partnership with CenExel for method comparison studies. The company successfully completed biocompatibility testing and in-clinic testing phases, key milestones for FDA submission targeted for Q4 2024.The company ended the quarter with $3.99 million in cash and established a $3 million ATM facility with Ladenburg Thalmann. However, management indicated current cash reserves may be insufficient for the next 12 months of operations, raising substantial doubt about continuing as a going concern unless additional capital is raised. Net loss widened to $2.69 million from $2.43 million in the prior year period.
Intelligent Bio Solutions Inc. reported Q1 FY2025 revenue of $872,287, a 10% increase from $796,094 in Q1 FY2024, driven by customer base expansion across 19 countries. Gross profit margin improved to 39.8% from 29.2% year-over-year, reflecting enhanced production efficiency and reduced direct costs. The company secured 22 new accounts during the quarter.Development and regulatory expenses rose significantly to $948,752 from $103,947 last year as the company advanced its FDA 510(k) clinical study plan, including a partnership with CenExel for method comparison studies. The company successfully completed biocompatibility testing and in-clinic testing phases, key milestones for FDA submission targeted for Q4 2024.The company ended the quarter with $3.99 million in cash and established a $3 million ATM facility with Ladenburg Thalmann. However, management indicated current cash reserves may be insufficient for the next 12 months of operations, raising substantial doubt about continuing as a going concern unless additional capital is raised. Net loss widened to $2.69 million from $2.43 million in the prior year period.
智能生物解决方案公司报告2025财年第一季度的营业收入为872,287美元，比2024财年第一季度的796,094美元增长了10%，这得益于在19个国家的客户基础扩展。毛利润率从去年同期的29.2%提升至39.8%，反映出生产效率的提高和直接成本的降低。公司在本季度获得了22个新客户。开发和监管费用显著上升，从去年的103,947美元增加至948,752美元，因为公司推进了FDA 510(k)临床学习计划，包括与CenExel的合作进行方法对比研究。公司成功完成了生物相容性测试和临床测试阶段，这些是针对2024年第四季度FDA提交的重要里程碑。公司季度末现金余额为399万美元，并与Ladenburg Thalmann建立了300万美元的ATM融资设施。然而，管理层表示，目前的现金储备对于未来12个月的运营可能不足，这对持续经营提出了重大疑虑，除非获得额外资金。净亏损从去年同期的243万美元扩大至269万美元。
智能生物解决方案公司报告2025财年第一季度的营业收入为872,287美元，比2024财年第一季度的796,094美元增长了10%，这得益于在19个国家的客户基础扩展。毛利润率从去年同期的29.2%提升至39.8%，反映出生产效率的提高和直接成本的降低。公司在本季度获得了22个新客户。开发和监管费用显著上升，从去年的103,947美元增加至948,752美元，因为公司推进了FDA 510(k)临床学习计划，包括与CenExel的合作进行方法对比研究。公司成功完成了生物相容性测试和临床测试阶段，这些是针对2024年第四季度FDA提交的重要里程碑。公司季度末现金余额为399万美元，并与Ladenburg Thalmann建立了300万美元的ATM融资设施。然而，管理层表示，目前的现金储备对于未来12个月的运营可能不足，这对持续经营提出了重大疑虑，除非获得额外资金。净亏损从去年同期的243万美元扩大至269万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！